Shackelford Pharma Inc. Confirms Three Human Phase 2 Trials on Track to Begin in 2021 and Announces March 31st Closing Date for Regulation A+ Offering
Vancouver BC, Canada (March 12, 2021) — Shackelford Pharma Inc. (“Shackelford” or the “Company”), a pharmaceutical company developing medicines targeting the endocannabinoid system to treat diseases with high unmet medical needs, has announced the final closing date of its Regulation A+ (“Reg A+”) offering of common shares of the Company (the “Offering”)as March 31, 2021.
The offering circular (the “Offering Circular”) stipulates the Offering will terminate on the earlier of (i) twelve (12) months after the commencement date of the Offering, unless earlier terminated or extended by the Company, (ii) the date on which the Maximum Offering (as defined in the Offering Circular) is sold, or (iii) when the Board of Directors of the Company elects to terminate the Offering (in each such case, the “Termination Date“). The Company’s Board of Directors has chosen to make March 31, 2021 the Termination Date for the Offering.
“The generous support of our investors in this Reg A+ financing has allowed us to move into a human trial program that is anticipated to include three human Phase 2 trials in 2021,” said Shackelford’s CEO Mark Godsy. “We of course welcome more investors in the next few weeks, before our successful Reg A is closed.”
Shackelford will stop accepting Reg A+ subscription agreements and payments as of 11:59PM Pacific Standard Time on March 31, 2021.
Investors who may be interested in purchasing our common shares are encouraged to do so in advance of the Termination Date to ensure your funding is processed in advance of this deadline. All investors should read our Offering Circular and related exhibits and consult with their financial, legal and tax professionals prior to investing.
The Offering was made effective on August 20, 2020, and officially launched in September of 2020. The Company is offering up to 10 million common shares at USD$1 per common share to both accredited and non-accredited investors in the United States of America, with a minimum investment threshold of 1500 shares or $1500. The Company’s Offering Circular can be viewed on EDGAR.
The Company is pleased to have welcomed more than 1200 investors into the company to date, helping Shackelford raise a substantial portion of the Offering amount. Proceeds from this Offering are being used to further the Company’s clinical program, specifically moving toward Phase 2 clinical trials in 2021 for its three initial indications – Childhood Epilepsy, Cluster Headaches and Mild Cognitive Impairment.
Questions related to this Offering, or general inquires to the Company can be made by calling us directly at 1-888-377-4225 Ext.1., or by emailing us at firstname.lastname@example.org. Additional company information is available on our website www.shackelfordpharma.com, where you are also be able to sign up to receive updates from Shackelford Pharma Inc. as we advance our clinical program.
On behalf of the Board of Directors
Mark Godsy, CEO
About Shackelford Pharma Inc.
Since 2009, Dr. Alan Shackelford has treated more than 25,000 patients suffering from a broad range of medically challenging conditions by targeting the endocannabinoid system. In his clinical practice, he compiled an in-depth database of patient treatments that is the largest of its kind in the world. In 2018 Alan and a team of medical, scientific and business experts created Shackelford Pharma, Inc. to leverage and apply on a commercial scale the insights, experience, and efficacy of Alan’s remarkable pioneering work. The Shackelford team is developing and commercializing unique cannabinoid-derived drugs and innovative delivery methods to serve millions of people. Please visit us at www.shackelfordpharma.com
Forward Looking Statements
This news release may contain both historical and forward-looking statements. Forward-looking statements relate to expectations, beliefs, projections, future plans and strategies, anticipated events or trends and similar matters that are not historical facts. Some of the statements herein constitute forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “should,” “will” and “would” or the negatives of these terms, or other comparable terminology. To the extent that this document contains forward-looking statements regarding our business, please be advised that our actual financial condition, operating results, and business performance may differ materially from that projected or estimated by us in forward-looking statements. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made.
Although the forward-looking statements in this document are based on our beliefs, assumptions, and expectations, taking into account all information currently available to us, we cannot guarantee future transactions, results, performance, achievements, or outcomes. No assurance can be made to any investor by anyone that the expectations reflected in our forward-looking statements will be attained, or that deviations from them will not be material and adverse. We undertake no obligation, other than as may be required by law, to re-issue this document or otherwise make public statements updating our forward-looking statements.
This news release does not constitute an offer to sell or a solicitation of an offer to buy any securities in the United States. In the United States under the Securities Act of 1933, any offer to sell securities must either be registered with the United States Securities and Exchange Commission (SEC) or meet certain qualifications to exempt it from such registration. An offering circular on Form 1-A was filed with the Securities and Exchange Commission (“SEC”) and was qualified by the SEC as of August 20, 2020. The offering of these securities was made only by means of an offering circular on Form 1-A.